Wnt/beta-Catenin Signaling Contributes to Vincristine-Induced Neuropathic Pain

Area of Science:

• Neuroscience
• Pharmacology
• Oncology

Background:

• Chemotherapy-induced neuropathic pain (CNP) is a significant challenge in cancer therapy, often limiting treatment efficacy.
• The precise molecular mechanisms driving CNP are not fully understood, hindering the development of targeted treatments.

Purpose of the Study:

• To investigate the role of Wnt/beta-catenin signaling in the development of vincristine-induced neuropathic pain (CNP).
• To explore the potential of targeting Wnt/beta-catenin signaling as a therapeutic strategy for CNP.

Main Methods:

• Chemotherapy-induced neuropathic pain (CNP) was modeled in male C57BL/6J mice using repeated intraperitoneal injections of vincristine (VCR).
• Wnt/beta-catenin signaling activation was assessed, along with the expression of inflammatory markers (TNF-alpha, MCP-1) and the MAPK/ERK pathway.
• The efficacy of blocking Wnt/beta-catenin signaling using inhibitors of Wnt response (IWR) administered intrathecally was evaluated.

Main Results:

• Vincristine administration significantly activated Wnt/beta-catenin signaling, leading to neuroinflammation (astrocyte and microglia activation) and the release of inflammatory cytokines.
• Activated Wnt/beta-catenin signaling further triggered the MAPK/ERK pathway in the spinal cord of CNP mice.
• Intrathecal administration of IWR effectively reduced VCR-induced neuropathic pain and inhibited the associated neuroinflammation and signaling pathway activation.

Conclusions:

• Wnt/beta-catenin signaling plays a crucial role in the pathogenesis of vincristine-induced neuropathic pain.
• Targeting Wnt/beta-catenin signaling presents a promising therapeutic avenue for alleviating chemotherapy-induced neuropathic pain.